The dose rate factor from interstitial irradiation with 103-palladium and 109-palladium.
D000818:Animals; D001859:Bone Neoplasms / Q000532:radiotherapy; D002277:Carcinoma / Q000532:radiotherapy; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy; D005260:Female; D005354:Fibrosarcoma / Q000532:radiotherapy; D006207:Half-Life; D006801:Humans; D008099:Liver / Q000528:radiation effects; D008113:Liver Neoplasms / Q000532:radiotherapy; D008115:Liver Regeneration; D008297:Male; D008545:Melanoma / Q000532:radiotherapy; D009132:Muscles / Q000528:radiation effects; D009336:Necrosis / Q000209:etiology; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000532:radiotherapy*; D010165:Palladium / Q000008:administration & dosage*; D011817:Rabbits; D011830:Radiation Effects; D011868:Radioisotopes / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D012878:Skin Neoplasms / Q000532:radiotherapy; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy; D014846:Vulvar Neoplasms / Q000532:radiotherapy
D011868:Radioisotopes; D010165:Palladium